Cell line-based xenograft mouse model of paediatric glioma stem cells mirrors the clinical course of the patient

• Published in: Carcinogenesis (New York) 2018-10, Vol.39 (10), p.1304-1309
• Main Authors: Larsson, Susanna, Wenger, Anna, Dósa, Sándor, Sabel, Magnus, Kling, Teresia, Carén, Helena
• Format: Article
• Language: English
• Subjects: Cancer and Oncology; Cancer och onkologi; Carcinogenesis; DNA methylation; glioblastoma; h3f3a; identification; mutations; Pediatrics; Pediatrik; tumors
• ISSN: 0143-3334; 1460-2180
• DOI: 10.1093/carcin/bgy091

We have established a robust and reliable cell line-based glioma stem cell xenograft mouse model, genetically and epigenetically similar to its originating patient tumours. The survival of patients and injected mice correlate significantly, demonstrating that the transplanted mice mimic the clinical course of the patient. Abstract The leading cause of cancer-related mortality among children is brain tumour, and glioblastoma multiforme (GBM) has the worst prognosis. New treatments are urgently needed, but with few cases and clinical trials in children, pre-clinical models such as patient-derived tumour xenografts (PDTX) are important. To generate these, tumour tissue is transplanted into mice, but this yields highly variable results and requires serial passaging in mice, which is time-consuming and expensive. We therefore aimed to establish a cell line-based orthotopic mouse model representative of the patient tumour. Glioma stem cell (GSC) lines derived from paediatric GBM were orthotopically transplanted into immunodeficient mice. Overall survival data were collected and histological analysis of the resulting neoplasias was performed. Genome-wide DNA methylation arrays were used for methylation and copy-number alterations (CNA) profiling. All GSC lines initiated tumours on transplantation and the survival of the mice correlated well with the survival of the patients. Xenograft tumours presented histological hallmarks of GBM, and were also classified as GBM by methylation profiling. Each xenograft tumour clustered together with its respective injected GSC line and patient tumour based on the methylation data. We have established a robust and reproducible cell line-based xenograft paediatric GBM model. The xenograft tumours accurately reflected the patient tumours and mirrored the clinical course of the patient. This model can therefore be used to assess patient response in pre-clinical studies.